References
- Dreyfus B, Vernant JP, Wechsler J, Imbert M, De Prost Y, Reyes F, et al. Refractory anaemia with an excess of myeloblasts and cutaneous vasculitis (author's transl). Nouv Rev Fr Hematol 1981;23:115-21.
- Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 1995;91:403-8. https://doi.org/10.1111/j.1365-2141.1995.tb05310.x
- Giannouli S, Voulgarelis M, Zintzaras E, Tzioufas AG, Moutsopoulos HM. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford) 2004;43:626-32. https://doi.org/10.1093/rheumatology/keh136
- Belizna C, Subra JF, Henrion D, Ghali A, Renier G, Royer M, et al. Prognosis of vasculitis associated myelodysplasia. Autoimmun Rev 2013;12:943-6. https://doi.org/10.1016/j.autrev.2013.01.005
- de Hollanda A, Beucher A, Henrion D, Ghali A, Lavigne C, Levesque H, et al. Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res (Hoboken) 2011;63:1188-94. https://doi.org/10.1002/acr.20504
- Enright H, Miller W. Autoimmune phenomena in patients with myelodysplastic syndromes. Leuk Lymphoma 1997;24:483-9. https://doi.org/10.3109/10428199709055585
- van Rijn RS, Wittebol S, Graafland AD, Kramer MH. Immunologic phenomena as the first sign of myelodysplastic syndrome. Ned Tijdschr Geneeskd 2001;145:1529-33.
- Al Ustwani O, Ford LA, Sait SJ, Block AM, Barcos M, Vigil CE, et al. Myelodysplastic syndromes and autoimmune diseases: case series and review of literature. Leuk Res 2013;37:894-9. https://doi.org/10.1016/j.leukres.2013.04.007
- Saif MW, Hopkins JL, Gore SD. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 2002;43:2083-92. https://doi.org/10.1080/1042819021000016186
- Braun T, Fenaux P. Myelodysplastic syndromes (MDS) and autoimmune disorders (AD): cause or consequence? Best Pract Res Clin Haematol 2013;26:327-36. https://doi.org/10.1016/j.beha.2013.09.003
- Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007;109:1536-42. https://doi.org/10.1002/cncr.22570
- Jin J, Yu M, Hu C, Ye L, Xie L, Chen F, et al. Alcohol consumption and risk of myelodysplastic syndromes: a meta-analysis of epidemiological studies. Mol Clin Oncol 2014;2:1115-20. https://doi.org/10.3892/mco.2014.376
- Du Y, Fryzek J, Sekeres MA, Taioli E. Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). Leuk Res 2010;34:1-5. https://doi.org/10.1016/j.leukres.2009.08.006
- Kiladjian JJ, Visentin G, Viey E, Chevret S, Eclache V, Stirnemann J, et al. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes. Haematologica 2008;93:381-9. https://doi.org/10.3324/haematol.11812
- Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B, et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007;110:847-50. https://doi.org/10.1182/blood-2007-01-067546
Cited by
- Vaskulitiden und eosinophile Lungenerkrankungen vol.15, pp.1, 2018, https://doi.org/10.1007/s10405-017-0158-2
- Vaskulitiden und eosinophile Lungenerkrankungen vol.59, pp.9, 2016, https://doi.org/10.1007/s00108-018-0479-1
- Vaskulitiden und eosinophile Lungenerkrankungen vol.77, pp.10, 2016, https://doi.org/10.1007/s00393-018-0561-z